Nature Reviews
Cancer and Nature Reviews Drug Discovery
are pleased to present a joint Focus on Kinases
in cancer. The Focus examines the role of kinase
signalling in cancer and the potential for developing
effective therapies that can modulate various kinase
pathways. Following the success of targeted kinase
inhibitor therapies such as imatinib and gefitinib
this continues to be a fast moving area of research.
Making gains on glioma
A small-molecule inhibitor of transforming growth factor-β (TGF-β) receptor I kinase could prove to be an effective treatment.... [more]
Getting on TRK
Tumour-suppressor function is most often disrupted in cancer cells through inactivating mutations.... [more]
Comparison shopping
The ability to inactivate multiple kinases is a desirable feature of a small-molecule inhibitor.... [more]
Multiple opponents
Patients with chronic myelogenous leukaemia, acute lymphoblastic leukaemia and gastrointestinal tumours.... [more]
REDD or dead?
Hypoxia-induced inactivation of the protein kinase mammalian target of rapamycin (mTOR).... [more]
Causing cancer spread
Solid tumours look for ways to escape their confines so that they can metastasize to different parts of the body.... [more]
Life and LYN
The association between BCR�ABL1 expression and chronic myelogenous leukaemia (CML) has been well documented.... [more]
Trial Watch
Results of a Phase II trial with the mitogen-activated protein kinase kinase (MEK) inhibitor CI-1040 are disappointing.... [more]
